HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy

References

• Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo MS, Borzacchiello G. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 2011; 10:140. Review; PMID:22078316; http://dx.doi.org/10.1186/1476-4598-10-140
   PubMed Web of Science ®Google Scholar
• Crusius K, Auvinen E, Steuer B, Gaissert H, Alonso A: The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp Cell Res 1998; 241:76-83; PMID:9633515; http://dx.doi.org/10.1006/excr.1998.4024
   PubMed Web of Science ®Google Scholar
• Paolini F, Curzio G, Melucci E, Terrenato I, Antoniani B, Carosi M, Mottolese M, Vici P, Mariani L, Venuti A. Human papillomavirus 16 E2 interacts with neuregulin receptor degradation protein 1 affecting ErbB-3 expression in vitro and in clinical samples of cervical lesions. Eur J Cancer 2016; 58:52-61; PMID:26963794; http://dx.doi.org/10.1016/j.ejca.2016.02.001
   PubMed Web of Science ®Google Scholar
• Venuti A, Salani D, Poggiali F, Manni V, Bagnato A. The E5 oncoprotein of human papillomavirus type 16 enhances endothelin-1-induced keratinocyte growth. Virology 1998; 248:1-5; PMID:9705249; http://dx.doi.org/10.1006/viro.1998.9227
   PubMed Web of Science ®Google Scholar
• Regan JA, Laimins LA. Bap31 is a novel target of the human papillomavirus E5 protein. J Virol 2008; 82:10042-51; PMID:18684816; http://dx.doi.org/10.1128/JVI.01240-08
   PubMed Web of Science ®Google Scholar
• Oh JM, Lee YI, Song YS, Kim WH, Juhnn YS. Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis 2009; 30:141-49; PMID:18849297; http://dx.doi.org/10.1093/carcin/bgn236
   PubMed Web of Science ®Google Scholar
• Burkhardt A, Willingham M, Gay C, Jeang KT, Schlegel R. The E5 oncoprotein of bovine papillomavirus is oriented asymmetrically in Golgi and plasma membranes. Virology 1989; 170:334-9; PMID:2541554; http://dx.doi.org/10.1016/0042-6822(89)90391-7
   PubMed Web of Science ®Google Scholar
• Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998; 12:2061-72; PMID:9649509; http://dx.doi.org/10.1101/gad.12.13.2061
   PubMed Web of Science ®Google Scholar
• Obalek S, Favre M, Szymanczyk J, Misiewicz J, Jablonska S, Orth G. Human papillomavirus (HPV) types specific of epidermodysplasia verruciformis detected in warts induced by HPV3 or HPV3-related types in immunosuppressed patients. J Investig Dermatol 1992; 98:936-41 ; PMID:1317396; http://dx.doi.org/10.1111/1523-1747.ep12460892
   PubMed Web of Science ®Google Scholar
• Hu L, Plafker K, Vorozhko V. Human papillomavirus E5 induces bi-nucleated cell formation by cell-cell fusion. Virology 2009; 384:125-34; PMID:19041112; http://dx.doi.org/10.1016/j.virol.2008.10.011
   PubMed Web of Science ®Google Scholar
• Hu L, Ceresa BP. Characterization of the plasma membrane localization and orientation of HPV16 E5 for cell-cell fusion. Virology 2009; 393:135-43 ; PMID:19712955; http://dx.doi.org/10.1016/j.virol.2009.07.034
   PubMed Web of Science ®Google Scholar
• Yang DH, Wildeman AG, Sharom FJ. Overexpression, purification, and structural analysis of the hydrophobic E5 protein from human papillomavirus type 16. Protein Expr Purif 2003; 30:1-10; PMID:12821315; http://dx.doi.org/10.1016/S1046-5928(03)00049-4
   PubMed Web of Science ®Google Scholar
• Valle FG, Banks L. The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J Gen Virol 1995; 76:1239-45; PMID:7730808; http://dx.doi.org/10.1099/0022-1317-76-5-1239
   PubMed Web of Science ®Google Scholar
• Genther Williams SM, Disbrow GL, Schlegel R, Lee D, Threadgill DW, Lambert PF. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Research 2005; 65:6534-42; PMID:16061632; http://dx.doi.org/10.1158/0008-5472.CAN-05-0083
   PubMed Web of Science ®Google Scholar
• Ashrafi GH, Pitts JD, Faccini AM, McLean P, O'Brien V, Finbow ME, Campo S. Binding of bovine papillomavirus type 4 E8 to ductin (16K proteolipid), down-regulation of gap junction intercellular communication and full cell transformation are independent events. J Gen Virol 2000; 81:689-94; PMID:10675405; http://dx.doi.org/10.1099/0022-1317-81-3-689
   PubMed Web of Science ®Google Scholar
• Grindlay GJ, Campo MS, O'Brien V. Transactivation of the cyclin A promoter by bovine papillomavirus type 4 E5 protein. Virus Res 2005; 108:29-38; PMID:15681052; http://dx.doi.org/10.1016/j.virusres.2004.07.010
   PubMed Web of Science ®Google Scholar
• Liu D-W, Yang Y-C, Lin H-F, Lin M-F, Cheng Y-W, Chu C-C, Tsao YP, Chen SL. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. J Virol 2007; 81:2869-79; PMID:17202211; http://dx.doi.org/10.1128/JVI.02256-06
   PubMed Web of Science ®Google Scholar
• Chen Y-F, Lin C-W, Tsao Y-P, Chen S-L. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol 2004; 78:1333-43; PMID:14722288; http://dx.doi.org/10.1128/JVI.78.3.1333-1343.2004
   PubMed Web of Science ®Google Scholar
• Massa S, Simeone P, Muller A, Benvenuto E, Venuti A, Franconi R. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther 2008; 19:354-64; PMID:18439124; http://dx.doi.org/10.1089/hum.2007.122
   PubMed Web of Science ®Google Scholar
• Cordeiro MN, Paolini F, Massa S, Curzio G, Illiano E, Duarte Silva AJ, et al. Anti-tumor effects of genetic vaccines against HPV major oncogenes. Hum Vaccin Immunother 2015; 11:45-52; PMID:25483514; http://dx.doi.org/10.4161/hv.34303
   PubMed Web of Science ®Google Scholar
• Gray E, Pett MR, Ward D, Winder DM, Stanley MA, Roberts I, Scarpini CG, Coleman N. In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis. Cancer Res 2010; 70:4081-91; PMID:20442284; http://dx.doi.org/10.1158/0008-5472.CAN-09-3335
   PubMed Web of Science ®Google Scholar
• Xu B, Chotewutmontri S, Wolf S, Klos U, Schmitz M, Dürst M, Schwarz E. Multiplex identification of Human Papillomavirus 16 DNA integration sites in cervical carcinomas. PLoS One 2013; 8:e66693; PMID:23824673; http://dx.doi.org/10.1371/journal.pone.0066693
   PubMedGoogle Scholar
• Sahab Z, Sudarshan SR, Liu X, Zhang Y, Kirilyuk A, Kamonjoh CM, et al. Quantitative measurement of human papillomavirus type 16 E5 oncoprotein levels in epithelial cell lines by mass spectrometry. J Virol 2012; 86:9465-73; PMID:22740411; http://dx.doi.org/10.1128/JVI.01032-12
   PubMed Web of Science ®Google Scholar
• Chang JL, Tsao YP, Liu DW, Huang SJ, Lee WH, Chen SL. The expression of HPV- 16 E5 protein in squamous neoplastic changes in the uterine cervix. J Biomed Sci 2001; 8:206-13; PMID:11287752; http://dx.doi.org/10.1007/BF02256414
   PubMed Web of Science ®Google Scholar
• Lorenzon L, Mazzetta F, Venuti A, Frega A, Torrisi MR, French D. In vivo HPV 16 E5 mRNA: expression pattern in patients with squamous intra-epithelial lesions of the cervix. J Clin Virol 2011; 52:79-83; PMID:21767984; http://dx.doi.org/10.1016/j.jcv.2011.06.007
   PubMed Web of Science ®Google Scholar
• French D, Belleudi F, Mauro MV, Mazzetta F, Raffa S, Fabiano V, Frega A, Torrisi MR. Expression of HPV16 E5 down-modulates the TGFbeta signaling pathway. Mol Cancer 2013; 12:38; PMID:23651589; http://dx.doi.org/10.1186/1476-4598-12-38
   PubMed Web of Science ®Google Scholar
• Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006; 11:2286-302. Review; PMID:16720315; http://dx.doi.org/10.2741/1971
   PubMed Web of Science ®Google Scholar
• Chen J, Xue Y, Poidinger M, Lim T, Chew SH, Pang CL, Abastado JP, Thierry F. Mapping of HPV transcripts in four human cervical lesions using RNAseq suggests quantitative rearrangements during carcinogenic progression. Virology 2014; 462-463:14-24; PMID:25092457; http://dx.doi.org/10.1016/j.virol.2014.05.026
   PubMed Web of Science ®Google Scholar
• Kho EY, Wang HK, Banerjee NS, Broker TR, Chow LT. HPV-18 E6 mutants reveal p53 modulation of viral DNA amplification in organotypic cultures. Proc Natl Acad Sci U S A 2013; 110:7542-9; PMID:23572574; http://dx.doi.org/10.1073/pnas.1304855110
   PubMed Web of Science ®Google Scholar
• Liu DW, Tsao YP, Hsieh CH, Hsieh JT, Kung JT, Chiang CL, Huang SJ, Chen SL. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing Human Papillomavirus Type 16 E5 Gene Reduces Tumor Growth. J Virol 2000; 74:9083-89; PMID:10982354; http://dx.doi.org/10.1128/JVI.74.19.9083-9089.2000
   PubMed Web of Science ®Google Scholar
• Accardi L, Paolini F, Mandarino A, Percario Z, Di Bonito P, Di Carlo V, Affabris E, Giorgi C, Amici C, Venuti A. In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. Int J Cancer 2014; 134:2742-7; PMID:24226851; http://dx.doi.org/10.1002/ijc.28604
   PubMed Web of Science ®Google Scholar
• Bedoui S, Heath WR, Mueller SN. CD4(+) T-cell help amplifies innate signals for primary CD8(+) T-cell immunity. Immunol Rev 2016; 272:52-64; PMID:27319342; http://dx.doi.org/10.1111/imr.12426
   PubMed Web of Science ®Google Scholar
• Ristriani T, Fournane S, Orfanoudakis G, Travé G, Masson M. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells. Oncogene 2009; 28:762-72; PMID:19015633; http://dx.doi.org/10.1038/onc.2008.422
   PubMed Web of Science ®Google Scholar
• Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout J W, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23:2242-49; PMID:7690326; http://dx.doi.org/10.1002/eji.1830230929
   PubMed Web of Science ®Google Scholar
• Brasier AR, Tate JE, Habener JF. Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. Biotechniques 1989; 7:1116-22; PMID:2698191
   PubMed Web of Science ®Google Scholar
• Venuti A, Massa S, Mett V, Vedova LD, Paolini F, Franconi R, Yusibov V. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine 2009; 27:3395-7; PMID:19200826; http://dx.doi.org/10.1016/j.vaccine.2009.01.068
   PubMed Web of Science ®Google Scholar